[PDF][PDF] The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)
T Biering-Sørensen, M Minamisawa, J Liu… - Eur J Heart …, 2021 - cytokinetics.com
Eur J Heart Fail, 2021•cytokinetics.com
The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure
and Function in Chronic Systolic Page 1 The Effect of the Cardiac Myosin Activator, Omecamtiv
Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure
(COSMIC-HF) Tor Biering-Sørensen1, Alexander I. Papolos2, John R. Teerlink2, G. Michael
Felker3, John JJV McMurray4, Jason C. Legg5, Fady I. Malik6, Narimon Honarpour5,
Christopher E. Kurtz5, Scott D. Solomon1 1Division of Cardiology, Brigham & Women’s …
and Function in Chronic Systolic Page 1 The Effect of the Cardiac Myosin Activator, Omecamtiv
Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure
(COSMIC-HF) Tor Biering-Sørensen1, Alexander I. Papolos2, John R. Teerlink2, G. Michael
Felker3, John JJV McMurray4, Jason C. Legg5, Fady I. Malik6, Narimon Honarpour5,
Christopher E. Kurtz5, Scott D. Solomon1 1Division of Cardiology, Brigham & Women’s …
BACKGROUND
• Systolic heart failure (HF) is associated with poor prognosis; mortality and morbidity remain high despite improvements in interventions.• Right ventricular (RV) dysfunction and pulmonary hypertension (PH) are common in left-sided HF
cytokinetics.com
